Menu Content
How may we help?
I am a new caregiver
I need information
I need a laugh
Home arrow News

Register
Why Register?

Login

Chat

CHAT NOW
There are 0 chat connections.
There are 0 logon users.
There are 0 chat rooms.

Calendar

May 2008 > »
M T W T F S S
28 29 30 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1
News
Alzheimer’s Starts Earlier for Heavy Drinkers, Smokers
Sunday, 04 May 2008
CHICAGO – Heavy drinkers and heavy smokers develop Alzheimer’s disease years earlier than people with Alzheimer’s who do not drink or smoke heavily, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008.

“These results are significant because it’s possible that if we can reduce or eliminate heavy smoking and drinking, we could substantially delay the onset of Alzheimer’s disease for people and reduce the number of people who have Alzheimer’s at any point in time,” said study author Ranjan Duara, MD, of the Wien Center for Alzheimer’s Disease at Mount Sinai Medical Center in Miami Beach, FL, and Fellow of the American Academy of Neurology.

“It has been projected that a delay in the onset of the disease by five years would lead to a nearly 50-percent reduction in the total number of Alzheimer’s cases,” said Duara. “In this study, we found that the combination of heavy drinking and heavy smoking reduced the age of onset of Alzheimer’s disease by six to seven years, making these two factors among the most important preventable risk factors for Alzheimer’s disease.”

The study looked at 938 people age 60 and older who were diagnosed with possible or probable Alzheimer’s disease. The researchers gathered information from family members on drinking and smoking history and determined whether the participants had the ?4 gene variant of the APOE gene, which increases the risk of Alzheimer’s disease. People with the ?4 variant also develop Alzheimer’s at an earlier age than those who do not have the gene variant.

Seven percent of the study participants had a history of heavy drinking, which was defined as more than two drinks per day. Twenty percent had a history of heavy smoking, which was defined as smoking one pack of cigarettes or more per day. And 27 percent had the APOE ?4 variant.

R
esearchers found that people who were heavy drinkers developed Alzheimer’s 4.8 years earlier than those who were not heavy drinkers. Heavy smokers developed the disease 2.3 years sooner than people who were not heavy smokers. People with APOE ?4 developed the disease three years sooner than those without the gene variant.

Adding the risk factors together led to earlier onset of the disease. People who had all three risk factors developed the disease 8.5 years earlier than those with none of the risk factors. The 17 people in the study with all three risk factors developed Alzheimer’s at an average age of 68.5 years; the 374 people with none of the three risk factors developed the disease at an average age of 77 years.

T
he study was supported by the Florida Department of Elder Affairs. The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, epilepsy, multiple sclerosis, Parkinson’s disease, and stroke. For more information about the American Academy of Neurology, visit www.aan.com.  
 
High Cholesterol in Your 40s Increases Risk of Alzheimer's Disease
Saturday, 26 April 2008

CHICAGO – People with high cholesterol in their early 40s are more likely to develop Alzheimer's disease than those with low cholesterol, according to research that will be presented at the upcoming American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008.


"Our findings show it would be best for both physicians and patients to attack high cholesterol levels in their 40s to reduce the risk of dementia," said study author Alina Solomon, MD, with the University of Kuopio in Finland. Solomon collaborated with Rachel Whitmer, PhD, senior author of the study and a research scientist with Kaiser Permanente Division of Research in Oakland, CA.


The study involved 9,752 men and women in northern California who underwent health evaluations between 1964 and 1973 when they were between the ages of 40 and 45 and remained with the same health plan through 1994. From 1994 to 2007, researchers obtained the participants' most recent medical records to find 504 people had a diagnosis of Alzheimer's disease and 162 had vascular dementia.


The study found people with total cholesterol levels between 249 and 500 milligrams were one-and-a-half times more likely to develop Alzheimer's disease than those people with cholesterol levels of less than 198 milligrams. People with total cholesterol levels of 221 to 248 milligrams were more than one-and-a-quarter times more likely to develop Alzheimer's disease.

"High mid-life cholesterol increased the risk of Alzheimer's disease regardless of midlife diabetes, high blood pressure, obesity, smoking and late-life stroke," said Solomon.

Solomon says conclusions regarding high mid-life cholesterol and the risk of vascular dementia were difficult to formulate as there are several types of vascular dementia that may have slightly different risk factors.



The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, epilepsy, multiple sclerosis, Parkinson’s disease, and stroke. For more information about the American Academy of Neurology, visit www.aan.com.


Information provided by the American Academy of Neurology

 
Alzheimer's Vaccine Clears Plaque but Has Little Effect on learning and Memory Impairment
Monday, 07 April 2008
UCI study suggests that combination of therapies provides best opportunity for Alzheimer’s treatment

A promising vaccine being tested for Alzheimer’s disease does what it is designed to do – clear beta-amyloid plaques from the brain – but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.

The findings suggest that treating the predominant pathology of Alzheimer’s disease – beta-amyloid plaques – by itself may have only limited clinical benefit if started after there is significant plaque growth. However, a combination of vaccination with therapies that also target related neuron damage and cognitive decline may provide the best treatment opportunity for people with this neurodegenerative disease. Study results appear in the April 2 issue of the Journal of Neuroscience.


“We’ve found that reducing plaques is only part of the puzzle to treat Alzheimer disease,” said study leader, UC Irvine neurobiologist Elizabeth Head. “Vaccines such as this one are a good first step for effective Alzheimer’s treatment, but complimentary treatments must be developed to address the complexity of the disease.”


Head and colleagues studied for a two-year period in aging canines the effect of a vaccine that is currently under clinical development for treating patients with Alzheimer’s disease. The vaccine contains the beta-amyloid 1-42 protein and stimulates the immune system to produce antibodies against this same protein that is in the brain plaques. Dogs are used for such studies because beta-amyloid plaques grow naturally in their brains and they exhibit cognitive declines similar to those seen in humans.


After the aged dogs with beta-amyloid-plaque growth were immunized (which is similar to starting a treatment in patients with Alzheimer’s disease), the researchers found, in comparison with non-treated aged dogs, little difference in the results of behavioral tests that measure cognitive loss. Later, brain autopsies showed that although plaques had been cleared from multiple brain regions –  including the entorhinal cortex, a region of the brain involved with learning and memory and primarily affected by Alzheimer’s – damaged neurons remained.

Head said this discovery helps explain why there was little difference in the behavioral test results between immunized and nonimmunized dogs. In addition, she added, it implies that after clearing beta-amyloid plaques from the brain, the next step is to repair these neurons. This approach will be critical for treating and reversing the effects of the Alzheimer’s disease.

Currently, Head and her colleagues are developing approaches to repair these damaged neurons and hope to test them clinically.

Head is a researcher with the UC Irvine Institute for Brain Aging and Dementia. Viorela Pop, Vitaly Vasilevko, Mary Ann Hill, Tommy Saing, Floyd Sarsoza, Michaela Nistor, Lori-Ann Christie, Saskia Milton, Charles Glabe and David Cribbs of UC Irvine; and Edward Barrett of the Lovelace Respiratory Research Institute in Albuquerque, N.M., assisted with the study. The National Institutes of Health supported the study, and the Lovelace Institute provided the canine study subjects.


Read more...
 
10 million U.S. baby boomers will develop Alzheimer's disease
Wednesday, 26 March 2008
 1 in 8 boomers will develop Alzheimer’s disease, according to new Alzheimer’s Association report

The Alzheimer’s Association estimates that 10 million baby boomers will develop Alzheimer’s disease in the United States, according to their new report released today, the 2008 Alzheimer’s Disease Facts and Figures.

The new report says the disease is poised to strike one out of eight baby boomers. According to the Alzheimer’s Association, now is the time to address this looming epidemic that currently has no effective disease-modifying treatments that halt or delay the progression of the disease.
Today, as many as 5.2 million Americans are living with Alzheimer’s disease, which includes between 200,000-500,000 people under age 65 with young-onset Alzheimer’s disease or other dementias. Experts predict by 2010, there will be almost a half million new cases of Alzheimer’s disease each year; and by 2050, there will be almost a million new cases each year.

The Association’s report details the escalation of Alzheimer’s disease, which now is the seventh-leading cause of death in the country and the fifth-leading cause of death for those over age 65. It also offers numerous statistics that convey the burden Alzheimer’s imposes on individuals, families, government, business, and the nation’s health and long-term care systems. For example:

  • Every 71 seconds, someone in America develops Alzheimer’s disease; by mid-century someone will develop Alzheimer’s every 33 seconds.
  • Women are nearly twice as likely as men to develop Alzheimer’s disease (17 percent vs. 9 percent). One in six women and one in ten men age 55 and older can expect to develop Alzheimer’s disease in their remaining lifetime. Although it may appear that being female is a risk factor, more women will develop Alzheimer’s because on average, women live longer than men, thereby having more time to develop the disease.
  • In 2007, there were nearly 10 million Americans age 18 and over providing 8.4 billion hours of unpaid care to people with Alzheimer’s disease valued at $89 billion, four times more than what Medicaid pays for nursing home care for people with Alzheimer’s disease and other dementias.
  • In addition, a quarter million American children age 8 to 18 years old are providing care to loved ones with Alzheimer’s.
  • There are 1 to 1.4 million “long-distance caregivers” in the United States. About 1 million live more than two hours or more away and another 400,000 live at least an hour away from their loved ones.  Many of these long-distance caregivers also incur higher caregiving-related expenses compared to other caregivers.
  • Seventy percent of people with Alzheimer’s and other dementias live at home where friends and family take care of them.
Read more...
  << Start < Prev 1 2 3 4 5 Next > End >>

Results 1 - 8 of 34

Inside the Brain:
An Interactive Tour

braintour.gif
Courtesy of the:
alzheimers-association.gif
My site was nominated for Best Health Blog! HealthCentral Top Site AwardCFA_logo_winner.jpg
© Copyright 2007 The KnowItAlz Group. Site Map.
RSS Feeds: Entries - News - Comments
Web design by plethoradesign.com